CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 1 SCOPE OF REPORT... 1 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 2 RELATED BCC RESEARCH REPORTS... 2 BCC ONLINE SERVICES... 3 DISCLAIMER... 3 CHAPTER TWO: SUMMARY... 4 SUMMARY TABLE GLOBAL DERMATOLOGICAL THERAPEUTICS REVENUE FORECAST BY MARKET SEGMENT, THROUGH 2013 ($ BILLIONS)... 5 SUMMARY FIGURE GLOBAL DERMATOLOGICAL THERAPEUTICS REVENUE FORECAST BY MARKET SEGMENT, 2008 AND 2013 (%)... 6 CHAPTER THREE: OVERVIEW... 7 HUMAN SKIN... 7 TABLE 1 FUNCTIONS OF THE SKIN... 7 TABLE 1 (CONTINUED)... 8 SKIN DISORDERS... 9 TABLE 2 DISORDERS OF THE SKIN... 9 TABLE 2 (CONTINUED)... 10 TABLE 2 (CONTINUED)... 11 TABLE 2 (CONTINUED)... 12 ACNE... 13 TABLE 3 TYPES OF ACNE... 13 ROSACEA... 13 TABLE 4 TYPES OF ROSACEA... 14 TABLE 5 DRUGS AND THEIR ACTION AGAINST ACNE AND ROSACEA... 14 BACTERIAL INFECTIONS OF THE SKIN... 15 TABLE 6 TYPES OF BACTERIAL INFECTIONS OF THE SKIN... 15 TABLE 6 (CONTINUED)... 16 TABLE 6 (CONTINUED)... 17 TABLE 7 SOME PRESCRIPTION DRUGS PRESCRIBED TO TREAT BACTERIAL SKIN INFECTIONS... 17 TABLE 7 (CONTINUED)... 18 TABLE 7 (CONTINUED)... 19 BENIGN SKIN GROWTHS OR TUMORS... 19 TABLE 8 TYPES OF BENIGN SKIN GROWTHS OR TUMORS... 19 TABLE 8 (CONTINUED)... 20
TABLE 9 SOME PRESCRIPTION DRUGS USED TO TREAT BENIGN SKIN GROWTHS... 20 TABLE 9 (CONTINUED)... 21 BULLOUS DISORDERS OR BLISTERING DISEASES... 21 TABLE 10 TYPES OF BULLOUS DISORDERS... 21 TABLE 10 (CONTINUED)... 22 TABLE 11 SOME PRESCRIPTION DRUGS USED TO TREAT BULLOUS SKIN DISORDERS... 22 TABLE 11 (CONTINUED)... 23 SKIN CANCERS... 23 TABLE 12 TYPES OF SKIN CANCERS... 23 TABLE 12 (CONTINUED)... 24 Types of Melanoma... 24 Lentigo Maligna Melanoma... 24 Superficial Spreading Melanoma... 25 Nodular Melanoma... 25 Acral-Lentiginous Melanoma... 25 TABLE 13 SKIN CANCER INCIDENCE IN THE U.S.... 26 TABLE 14 SOME PRESCRIPTION DRUGS USED TO TREAT CUTANEOUS CARCINOMAS... 26 CORNIFICATION DISORDERS... 27 Calluses and Corns... 27 TABLE 15 TYPES OF CALLUSES AND CORNS... 27 Ichthyosis or Dry Skin... 27 TABLE 16 TYPES OF ICHTHYOSIS... 27 TABLE 16 (CONTINUED)... 28 Keratosis Pilaris... 28 TABLE 17 TYPES OF KERATOSIS PILARIS... 28 Sebaceous Cysts... 29 Dermatitis... 29 TABLE 18 TYPES OF DERMATITIS... 29 TABLE 18 (CONTINUED)... 30 TABLE 19 SOME DRUGS PRESCRIBED FOR DERMATITIS... 31 Fungal Infections of the Skin... 31 TABLE 20 TYPES OF FUNGAL INFECTIONS OF THE SKIN... 32 TABLE 20 (CONTINUED)... 33 TABLE 21 SOME DRUGS PRESCRIBED TO TREAT FUNGAL INFECTIONS OF THE SKIN... 33 TABLE 21 (CONTINUED)... 34 HYPERSENSITIVITY AND INFLAMMATORY DISORDERS... 34 Acute Febrile Neutrophilic Dermatosis (Sweet s Syndrome)... 34 Drug Eruptions and Reactions... 34 TABLE 22 TYPES OF DRUG REACTIONS AND TYPICAL CAUSATIVE AGENTS... 35
TABLE 22 (CONTINUED)... 36 Erythema Multiforme... 36 TABLE 23 TYPES OF ERYTHEMA MULTIFORME... 37 Erythema Nodosum... 37 Granuloma Annulare... 37 Panniculitis... 37 Pyoderma Gangrenosum... 37 Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis... 38 Bed Sore... 38 Pityriasis Rosea... 38 TABLE 24 SOME DRUGS PRESCRIBED TO TREAT HYPERSENSITIVITY AND INFLAMMATORY DISORDERS... 38 TABLE 24 (CONTINUED)... 39 PARASITIC INFECTIONS OF THE SKIN... 39 TABLE 25 TYPES OF PARASITIC INFECTION OF THE SKIN... 39 TABLE 25 (CONTINUED)... 40 TABLE 26 SOME DRUGS PRESCRIBED TO TREAT PARASITIC INFECTIONS OF THE SKIN... 41 PSORIASIS AND SCALING DISEASES... 41 TABLE 27 TYPES OF PSORIASIS AND SCALING DISEASES... 42 Psoriasis Treatment... 43 PIGMENTATION DISORDERS... 43 TABLE 28 TYPES OF PIGMENTATION DISORDERS... 44 Birthmarks... 44 Poison Ivy... 44 TABLE 29 SOME PRESCRIPTION DRUGS FOR PIGMENTATION DISORDERS... 45 REACTIONS TO SUNLIGHT... 45 Aging... 45 Actinic Keratoses... 46 Skin Cancers... 46 Photosensitivity... 46 TABLE 30 TYPES OF PHOTOSENSITIVITY... 46 Sunburn... 47 SWEATING DISORDERS... 47 TABLE 31 TYPES OF SWEATING DISORDERS... 47 VIRAL SKIN DISEASES... 48 TABLE 32 TYPES OF VIRAL SKIN DISEASES... 48 TABLE 32 (CONTINUED)... 49 TABLE 33 SOME DRUGS PRESCRIBED TO TREAT VIRAL DISEASES OF THE SKIN... 49 TABLE 33 (CONTINUED)... 50 COMMON DIAGNOSTIC TESTS FOR SKIN DISORDERS... 50 DERMOSCOPY... 50
PATCH TESTING... 50 SKIN BIOPSY... 51 CULTURE... 51 PHOTOTESTS... 51 MORBIDITY/PREVALENCE... 52 TABLE 34 SKIN DISORDER MORBIDITY IN THE U.S. BY AGE AND CAUSE (THOUSANDS)... 53 THERAPEUTIC PROCEDURES FOR THE SKIN... 53 CANCER SURGERY... 53 Excisional Biopsy to Remove Skin Cancer... 53 Curettage and Electrocautery... 54 Mohs Micrographic Surgery (MMS)... 54 Wide Local Excision... 54 Skin Grafting... 54 Lymph Node Removal... 55 CHEMICAL PEELS... 56 CRYOTHERAPY/CRYOSURGERY... 57 Ice Packs... 57 Cold Gel Packs... 58 Ice Immersion... 58 Ice Massage... 58 Vapocoolant Sprays... 58 RADIOTHERAPY... 58 CHEMOTHERAPY... 59 Chemotherapy Creams... 59 Chemotherapy into a Vein... 59 LASER SURGERY... 60 TABLE 35 SKIN CONDITIONS REQUIRING ONLY LASER SURGERY... 60 TABLE 35 (CONTINUED)... 61 TABLE 35 (CONTINUED)... 62 Carbon Dioxide Laser... 62 YAG Laser... 63 Pulsed Dye Laser or Argon Laser... 63 Excimer Laser... 63 TABLE 36 ADVANTAGES AND DISADVANTAGES OF EXCIMER LASER... 64 PHOTODYNAMIC THERAPY... 64 TABLE 37 VARIOUS CANCERS TREATABLE BY PDT... 65 Application in Dermatology... 66 TABLE 38 VARIOUS SKIN DISORDERS TREATABLE BY PDT... 67 Goeckerman Treatment... 67 PUVA... 67 Ultraviolet B Phototherapy... 68 Broadband... 68 Narrowband... 68
TABLE 39 ADVANTAGES AND DISADVANTAGES OF UVB THERAPY... 69 SCLEROTHERAPY... 69 CHAPTER FOUR: PRESCRIPTION DERMATOLOGICAL DRUGS... 70 SYSTEMIC DRUGS... 70 ACITRETIN... 71 CLINDAMYCIN... 72 ERYTHROMYCIN... 72 CYCLOSPORINE... 73 TABLE 40 ADVANTAGES AND DISADVANTAGES OF CYCLOSPORINE... 74 METHOTREXATE... 74 TABLE 41 ADVANTAGES AND DISADVANTAGES OF METHOTREXATE... 75 THALIDOMIDE... 75 SYSTEMIC ANTIBACTERIAL AGENTS... 76 Antileprotic Drugs (Including Dapsone)... 76 Antimalarial Drugs (Including Hydroxychloroquine)... 77 SYSTEMIC ANTIFUNGAL AGENTS... 78 SYSTEMIC ANTIHISTAMINES... 78 SYSTEMIC ANTIPARASITIC AGENTS... 79 SYSTEMIC ANTIPRURITIC AGENTS... 79 SYSTEMIC ANTIVIRAL AGENTS... 79 SYSTEMIC CORTICOSTEROIDS... 80 SYSTEMIC INTERFERONS... 80 SYSTEMIC RETINOID... 81 OTHER SYSTEMIC DRUGS... 82 6-Thioguanine... 82 Hydroxyurea... 82 Mycophenolate Mofetil... 82 Sulfasalazine... 83 BIOLOGICAL THERAPIES (BIOLOGICS)... 83 Colchicine... 84 CYTOTOXIC AND IMMUNOSUPPRESSIVE DRUGS... 85 Retinoids... 86 Hormones and Anti-Androgens... 86 Hormones and (Continued)... 87 TOPICAL TREATMENTS... 88 ACICLOVIR... 88 TOPICAL RETINOIDS... 88 ANTHRALIN... 89 TABLE 42 ADVANTAGES AND DISADVANTAGES OF ANTHRALIN... 89 COAL TAR... 89 TABLE 43 ADVANTAGES AND DISADVANTAGES OF COAL TAR... 90 CORTICOSTEROIDS... 90 TABLE 44 ADVANTAGES AND DISADVANTAGES OF CORTICOSTEROIDS91 TABLE 45 TOPICAL CORTICOSTEROIDS, 2004... 91
TABLE 45 (CONTINUED)... 92 TABLE 45 (CONTINUED)... 93 RETINOID: TAZAROTENE... 94 TABLE 46 ADVANTAGES AND DISADVANTAGES OF TAZAROTENE... 94 VITAMIN D3: CALCIPOTRIENE... 94 TABLE 47 ADVANTAGES AND DISADVANTAGES OF CALCIPOTRIOL... 95 CAPSAICIN... 96 TOPICAL MEDICATIONS IN CLINICAL TRIALS... 96 MOISTURIZERS AND SCALE REMOVERS... 97 TABLE 48 DRUG TREATMENTS FOR SKIN DISEASE INTRODUCED IN 2006... 97 TABLE 48 (CONTINUED)... 98 TABLE 48 (CONTINUED)... 99 TABLE 48 (CONTINUED)... 100 TABLE 48 (CONTINUED)... 101 TABLE 48 (CONTINUED)... 102 CHAPTER FIVE: TECHNOLOGY REVIEW... 103 EMERGING TECHNOLOGIES IN DERMATOLOGY... 103 DNA MICROARRAY TECHNOLOGY IN DERMATOLOGY... 103 ADVANCES IN THE TREATMENT OF VARICOSE VEINS... 103 EMERGING TREATMENT OF ATOPIC DERMATITIS... 103 EMERGING DRUGS FOR ICHTHYOSIS... 104 PROGRESS IN THE MANAGEMENT OF ACNE... 104 PLASMA SKIN REGENERATION TECHNOLOGY... 104 TABLE 49 NEW TECHNOLOGIES IN DERMATOLOGY... 105 TABLE 49 (CONTINUED)... 106 PERMEATION ENHANCEMENT TECHNOLOGIES... 106 Drug Permeation Enhancement via Buccal Route... 107 Thiomatrix: Permeation Enhancement... 108 Merrion s Technology: Gastrointestinal Permeation Enhancement Technology (GIPET)... 108 FIGURE 1 GASTROINTESTINAL PERMEATION ENHANCEMENT TECHNOLOGY... 108 Transdermal Protein Delivery or Measurement Using Low- Frequency Sonophoresis... 109 RADIOTHERAPY... 110 External Radiotherapy... 111 Conformal Radiotherapy... 111 Intensity Modulated Radiotherapy... 111 Internal Radiotherapy... 112 Radioactive Implants... 112 Radioactive Liquids... 112 Radioactive (Continued)... 113 PLASMA SKIN REGENERATION... 114
Plasma Skin (Continued)... 115 Plasma Skin (Continued)... 116 CHAPTER SIX: PATENT ANALYSIS... 117 PATENT ISSUE TRENDS IN UNITED STATES... 117 FIGURE 2 U.S. PATENT TRENDS, 1990 2001... 117 TABLE 50 NUMBER OF U.S. PATENTS ISSUED, 2003 TO JULY 31, 2008. 118 TABLE 51 COMPANIES AND NUMBER OF U.S. PATENTS FILED BY THEM, 2003 TO JULY 31, 2008... 118 TABLE 52 RECENT DERMATOLOGY U.S. PATENTS... 119 TABLE 52 (CONTINUED)... 120 TABLE 52 (CONTINUED)... 121 TABLE 52 (CONTINUED)... 122 PATENT ISSUE TRENDS IN EUROPE... 122 TABLE 53 EUROPEAN DERMATOLOGICAL PATENTS, 2003 JULY 2008. 122 TABLE 54 RECENT PATENTS ISSUED BY THE EPO... 123 TABLE 54 (CONTINUED)... 124 CHAPTER SEVEN: INDUSTRY PARTICIPANT PROFILES... 125 MANUFACTURERS OF DERMATOLOGICAL DRUGS... 125 AGI DERMATICS... 125 ALLERGAN, INC.... 125 AMGEN, INC... 126 ANACOR PHARMACEUTICALS... 126 ANIKA THERAPEUTICS, INC.... 127 ASTELLAS US, LLC... 128 CHESTER VALLEY PHARMACEUTICALS, INC.... 129 CORIA LABORATORIES, LTD.... 129 CORIA LABORATORIES, LTD.... 129 DERMIK LABORATORIES, INC.... 129 DUSA PHARMACEUTICALS, INC.... 130 EISAI, INC.... 130 FERNDALE LABORATORIES, INC.... 131 GALDERMA LABORATORIES... 131 GENENTECH, INC.... 131 ISOLAGEN, INC.... 132 LEO PHARMA A/S... 132 MEDICIS PHARMACEUTICAL CORP.... 133 MEDIMETRIKS PHARMACEUTICALS, INC.... 134 MERZ PHARMA UK, LTD.... 134 NEOSIL, INC.... 135 NYCOMED U.S., INC.... 135 OBAGI MEDICAL PRODUCTS, INC.... 136 ONSET THERAPEUTICS... 137 ORTHONEUTROGENA... 137
PIERRE FABRE PHARMACEUTICALS, INC.... 138 PRIME PHARMACEUTICALS CORP.... 138 QLT, INC.... 138 QUINNOVA PHARMACEUTICALS... 139 SCHERING-PLOUGH CORP.... 139 SINCLAIR PHARMACEUTICALS... 139 SKINMEDICA, INC.... 140 STIEFEL LABORATORIES, INC.... 141 SUMMERS LABORATORIES, INC.... 141 SYNTOPIX GROUP, PLC... 141 TRIAX PHARMACEUTICALS, LLC... 142 VALEANT PHARMACEUTICALS INTERNATIONAL... 142 VALEO PHARMA, INC.... 143 WARNER CHILCOTT, LTD.... 144 XOMA, LTD.... 144 NON-COMMERCIAL ORGANIZATIONS... 145 AFRICAN ASSOCIATION OF DERMATOLOGY... 145 AMERICAN ACADEMY OF DERMATOLOGY (AAD)... 145 AMERICAN BEHCET S DISEASE ASSOC., INC.... 145 AMERICAN CELIAC SOCIETY... 145 AMERICAN HEMOCHROMATOSIS SOCIETY, INC.... 145 AMERICAN LUPUS SOCIETY... 146 AMERICAN SKIN ASSOCIATION, INC.... 146 AMERICAN SOCIAL HEALTH ASSOC.... 146 ARTHRITIS FOUNDATION... 146 ASIAN DERMATOLOGICAL ASSOCIATION... 146 ASSOCIATION OF PROFESSORS OF DERMATOLOGY... 147 ATAXIA-TELANGIECTASIA CHILDREN S PROJECT... 147 BASAL CELL CARCINOMA NEVUS SYNDROME/GORLIN SYNDROME... 147 BAY AREA LUPUS FOUNDATION... 147 BLOOM S SYNDROME REGISTRY... 147 BRITISH ASSOCIATION OF DERMATOLOGISTS... 148 CELIAC DISEASE FOUNDATION... 148 CELIAC SPRUE ASSOCIATION/USA... 148 CICATRICIAL ALOPECIA RESEARCH FOUNDATION... 148 COALITION OF SKIN DISEASES... 148 CORNELIA DE LANGE SYNDROME FOUNDATION, INC.... 149 CUTANEOUS LYMPHOMA FOUNDATION... 149 DERMATOLOGY FOUNDATION... 149 DERMATOLOGY NURSES ASSOCIATION (DNA)... 149 DERMATOPATHOLOGY FOUNDATION... 149 DYSAUTONOMIA FOUNDATION, INC.... 149 DYSTROPHIC EPIDERMOLYSIS BULLOSA... 150
THE ECTODERMAL DYSPLASIA SOCIETY... 150 EHLERS DANLOS NATIONAL FOUNDATION (EDNF)... 150 EHLERS-DANLOS SYNDROME FOUNDATION... 150 EUROPEAN ACADEMY FOR DERMATOLOGY AND VENEREOLOGY... 150 EADV Administrative Office... 151 THE EUROPEAN DERMATOLOGY FORUM... 151 EUROPEAN SOCIETY FOR DERMATOLOGICAL RESEARCH... 151 EUROPEAN UNION OF MEDICAL SPECIALISTS... 151 FOUNDATION FOR ICHTHYOSIS AND RELATED SKIN TYPES (F.I.R.S.T.)... 152 GLUTEN INTOLERANCE GROUP (DERMATITIS HERPETIFORMIS)... 152 HEMOCHROMATOSIS RESEARCH FOUNDATION... 152 HIDRADENITIS SUPPURATIVA FOUNDATION, INC.... 152 HISTIOCYTOSIS ASSOCIATION OF AMERICA... 153 INFLAMMATORY SKIN DISEASE INSTITUTE (ISDI)... 153 INTERNATIONAL FOUNDATION FOR DERMATOLOGY... 153 THE INTERNATIONAL LEAGUE OF DERMATOLOGICAL SOCIETIES OFFICE... 153 INTERNATIONAL PEMPHIGUS PEMPHIGOID FOUNDATION.. 153 THE INTERNATIONAL SOCIETY OF DERMATOPATHOLOGY... 154 KLIPPEL-TRENAUNAY SUPPORT GROUP... 154 LUPUS FOUNDATION OF AMERICA, INC.... 154 LYMPHOMA RESEARCH FOUNDATION... 154 LYMPHOMATOID PAPULOSIS CENTRAL REGISTRY... 154 MARFAN ASSOC. U.K.... 155 THE MELANOMA RESEARCH FOUNDATION... 155 MUSCULAR DYSTROPHY ASSOC... 155 MYOSITIS ASSOCIATION OF AMERICA (MAA)... 155 NATIONAL ALOPECIA AREATA FOUNDATION (NAAF)... 155 NATIONAL ATAXIA FOUNDATION... 156 NATIONAL ECZEMA ASSOCIATION (NEA)... 156 NATIONAL ECZEMA ASSOCIATION FOR SCIENCE AND EDUCATION... 156 NATIONAL ECZEMA SOCIETY... 156 NATIONAL EPIDERMOLYSIS BULLOSA REGISTRY... 156 NATIONAL FOUNDATION FOR ECTODERMAL DYSPLASIAS... 157 NATIONAL FOUNDATION FOR VITILIGO AND PIGMENT DISORDERS... 157 NATIONAL INCONITENTIA PIGMENTI FOUNDATION... 157 NATIONAL MEDICAL ASSOC.... 157 NATIONAL NEUROFIBROMATOSIS FOUNDATION... 157
NATIONAL ORGANIZATION FOR ALBINISM AND HYPOPIGMENTATION (NOAH)... 158 NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD)... 158 THE NATIONAL PEMPHIGUS FOUNDATION... 158 NATIONAL PSORIASIS FOUNDATION... 158 NATIONAL REGISTRY FOR ICHTHYOSIS AND RELATED DISORDERS... 158 NATIONAL VITILIGO FOUNDATION... 159 NEVOID BASAL CELL CARCINOMA SYNDROME SUPPORT NETWORK... 159 PACHYONYCHIA CONGENITA PROJECT... 159 THE PSORIASIS ASSOC.... 159 SCLERODERMA FEDERATION, INC.... 159 SCLERODERMA FOUNDATION... 160 SCLERODERMA RESEARCH FOUNDATION... 160 THE SCLERODERMA SOCIETY... 160 SOCIETY FOR INVESTIGATIVE DERMATOLOGY (SID)... 160 SOCIETY FOR PEDIATRIC DERMATOLOGY (SPD)... 160 THE STURGE-WEBER FOUNDATION... 161 THE VITILIGO SOCIETY, U.K.... 161 VITILIGO SUPPORT INTERNATIONAL... 161 VZV RESEARCH FOUNDATION... 161 XERODERMA PIGMENTOSUM SOCIETY... 161 TABLE 55 DERMATOLOGICAL ASSOCIATIONS... 162 TABLE 55 (CONTINUED)... 163 STRATEGIC ALLIANCES IN THE DERMATOLOGY MARKET... 163 MERGERS & ACQUISITIONS... 163 TABLE 56 SIGNIFICANT MERGERS AND ACQUISITIONS (2005 2008)... 164 TABLE 56 (CONTINUED)... 165 TABLE 56 (CONTINUED)... 166 VENTURE CAPITAL DEALS... 166 CHAPTER EIGHT: REGULATORY PREVIEW... 167 DRUG REGULATION IN THE UNITED STATES... 167 LICENSES FOR MEDICAL DEVICES... 168 DRUG REGULATION IN THE UNITED KINGDOM... 168 LICENSES FOR DRUGS... 169 DRUG AND EQUIPMENT APPROVAL IN EUROPE... 169 LICENSES FOR MEDICAL EQUIPMENT... 170 REIMBURSEMENT FOR DERMATOLOGICAL TREATMENT... 171 REIMBURSEMENT IN THE UNITED STATES... 171 REIMBURSEMENT IN EUROPE... 172 Reimbursement in Europe (Continued)... 173 CHAPTER NINE: MARKET METRICS... 174
MARKET TRENDS... 174 BIG PHARMA S FOCUS ON BLOCKBUSTER DRUGS ENABLES SPECIALTY FOCUS BY SMALL AND MEDIUM-SIZED FIRMS174 COSMETIC/AESTHETIC DERMATOLOGY FACES DOWNTURN 174 CHANGES IN REIMBURSEMENT AND OTHER LEGISLATION ARE CREATING UNCERTAINTY... 175 Managed Care Issues... 175 Medical Liability... 175 Physician Quality Reporting Initiative (PQRI)... 176 Dermatologic Surgery... 176 Cosmetic Procedure Tax... 177 INCREASED USE OF GENERICS IN PRESCRIPTION DERMATOLOGY... 177 DIFFICULTIES IN DETERMINATION OF BIOAVAILABILITY OF TOPICAL DRUGS... 178 PHYSICIAN SHORTAGE AND PARAMEDIC INFLUX IN DERMATOLOGY... 178 CERTIFICATION EXAM FOR NURSE PRACTITIONERS IN DERMATOLOGY NOW AVAILABLE... 179 USE OF PROCEDURE-THERAPY AND SPECIFIC DRUGS IN DERMATOLOGY... 179 POLLUTION CONTRIBUTES TO RISE IN ATOPIC DERMATITIS179 MANUFACTURERS OF TNF-BLOCKER DRUGS ORDERED TO HIGHLIGHT RISK OF FUNGAL INFECTIONS... 180 HIGHER CO-PAYS FOR BIOLOGICS IMPACTS PRESCRIPTIONS181 U.S. DERMATOLOGICAL MARKET... 181 TABLE 57 LEADING DRUGS PRESCRIBED BY OFFICE-BASED DERMATOLOGISTS ALL INDICATIONS, 2008 (THOUSANDS)... 181 PRESCRIPTION DATA FOR ACNE... 182 Prescription Data for Acne (Continued)... 183 FIGURE 3 PRESCRIBING OF ORAL ANTIBIOTICS FOR THE INTITIAL TREATMENT OF ACNE: CURRENT AND IN 1 YEAR (N=75)... 184 FIGURE 4 PRESCRIBING OF TOPICAL ANTIBIOTICS/RETINOIDS FOR ACNE: CURRENT AND IN 1 YEAR (N=75)... 185 TABLE 58 U.S. DERMATOLOGICAL THERAPEUTICS MARKET: REVENUE FORECAST BY MARKET SEGMENT, THROUGH 2013 ($ BILLIONS)... 186 FIGURE 5 SHARE OF SEGMENTS IN U.S. PRESCRIPTION DERMATOLOGY MARKET, 2008 AND 2013 (%)... 186 FIGURE 5 (CONTINUED)... 187 FIGURE 6 LEADING PRESCRIPTION DRUG REVENUES IN GLOBAL DERMATOLOGY MARKET, 2008 ($ MILLIONS)... 187 FIGURE 6 (CONTINUED)... 188 ENBREL... 188
FIGURE 7 ENBREL SALES IN GLOBAL DERMATOLOGY MARKET BY GEOGRAPHY, 2008 (%, TOTAL REVENUE = $ 3,230 MILLION)... 189 BOTOX... 190 FIGURE 8 BOTOX SALES IN THE GLOBAL DERMATOLOGY MARKET BY GEOGRAPHY, 2008 (%, TOTAL REVENUE = $ 1,200 MILLION... 190 FIGURE 8 (CONTINUED)... 191 LOCERYL... 191 FIGURE 9 LOCERYL SALES IN GLOBAL DERMATOLOGY MARKET BY GEOGRAPHY, 2008 (%, TOTAL = $350 MILLION... 192 FIGURE 10 GLOBAL DERMATOLOGICAL PRESCRIPTION MARKET BY REGIONAL SHARE FUTURE OUTLOOK, 2011 (%)... 193 TABLE 59 MARKET SHARE OF PRESCRIPTION DRUG MANUFACTURERS, 2005 2007 ($ MILLIONS)... 194 GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET... 194 FIGURE 11 GLOBAL DERMATOLOGICAL MARKET BY REGIONAL SHARE, 2008 (%)... 195 TABLE 60 GLOBAL DERMATOLOGICAL THERAPEUTICS REVENUE FORECAST BY MARKET SEGMENT, THROUGH 2013... 196 FIGURE 12 GLOBAL PRESCRIPTION DERMATOLOGY MARKET SHARE BY SEGMENT, 2008 (%)... 196 FIGURE 12 (CONTINUED)... 197 GLOBAL DERMATOLOGICAL (CONTINUED)... 198 GLOBAL DERMATOLOGICAL (CONTINUED)... 199